Bluejay Diagnostics (BJDX) Net Cash Flow (2020 - 2026)

Bluejay Diagnostics has disclosed Net Cash Flow across 7 years of filings, most recently posting -$1.5 million for Q1 2026.

• Net Cash Flow for Q1 2026 came in at -$1.5 million, down 24.84% year-over-year; the trailing twelve-month figure through Mar 2026 was $742089.0 (up 63.12% YoY), and the FY2025 annual result was $862930.0, down 58.78% from the prior year.
• Net Cash Flow came in at -$1.5 million for Q1 2026 at Bluejay Diagnostics, down from $2.3 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $5.4 million in Q2 2024 to a low of -$3.3 million in Q1 2023.
• The 5-year median for Net Cash Flow is -$1.5 million (2026), against an average of -$893980.1.
• Peak annual rise in Net Cash Flow reached 420.98% in 2024, while the deepest fall reached 9711.14% in 2024.
• Bluejay Diagnostics' Net Cash Flow stood at -$3.2 million in 2022, then advanced by 9.87% to -$2.9 million in 2023, then jumped by 49.32% to -$1.5 million in 2024, then surged by 255.2% to $2.3 million in 2025, then tumbled by 165.61% to -$1.5 million in 2026.
• The last three Net Cash Flow figures came in at -$1.5 million (Q1 2026), $2.3 million (Q4 2025), and -$1.4 million (Q3 2025), per Business Quant data.